American Society of Hematology
The world's largest haematology society, whose December annual meeting is where the pivotal leukaemia, lymphoma and myeloma results are first presented.
Founded in 1958, ASH has more than 18,000 members and publishes Blood and Blood Advances. Its annual meeting, held each December, is the venue for the major blood cancer trials, from CAR-T and bispecific antibody results to venetoclax combinations and MRD-guided therapy, and its late-breaking abstract session regularly changes practice. ASH issues clinical practice guidelines, runs the ASH Research Collaborative with its data hub and the Sickle Cell Disease and Cancer Clinical Trials Networks, funds scholar awards and global capacity building, and advocates on drug access and research funding. ASH-EHA and ASH-ASCO joint guidelines link it to its European and oncology counterparts.
- ASH Annual Meeting (December)
- Blood and Blood Advances
- Clinical practice guidelines
- ASH Research Collaborative data hub
- Scholar awards and global programmes
Translated bortezomib and lenalidomide from bench to bedside, helping turn myeloma from a two-year to a decade-plus disease.
Discovered the JAK2 mutation behind most myeloproliferative neoplasms and defined the genetics of clonal haematopoiesis.
Discovered how lenalidomide works, launching the field of molecular-glue degraders, and defined clonal haematopoiesis before leading Dana-Farber.